Skip to main content
. 2020 Feb;20(2):240–249. doi: 10.1016/S1473-3099(19)30470-0

Table 2.

Estimated PAF and number of incident HIV infections in 2016 attributable to HSV-2 infection among individuals aged 15–49 years, overall and by WHO region

PAF of incident HIV infection attributable to HSV-2 infection
Number of incident HIV infections attributable to all HSV-2 infections Number of incident HIV infections from sexual transmission Number of incident HIV infections from all routes of HIV transmission§
All HSV-2 infections Established HSV-2 infections Recently acquired HSV-2 infections All incident HIV infection*
African 37·1% (28·7–46·3) 33·7% (24·8–43·1) 3·4% (1·3–7·5) 36·4% (28·1–45·4) 346 000 (253 000–454 000) 932 000 951 000
Americas 21·3% (14·7–29·4) 19·2% (12·4–27·5) 2·1% (0·8–4·6) 20·5% (14·1–28·2) 30 000 (20 000–42 000) 140 000 146 000
Eastern Mediterranean 12·3% (7·5–20·1) 11·5% (6·6–19·5) 0·8% (0·3–1·9) 5·9% (3·6–9·7) 2000 (1000–4000) 16 000 33 000
European 11·6% (7·0–19·4) 10·6% (5·9–18·3) 1·0% (0·4–2·2) 7·4% (4·5–12·4) 15 000 (9000–24 000) 126 000 198 000
South-East Asian 12·4% (6·2–22·1) 11·2% (5·1–21·2) 1·2% (0·4–2·6) 11·5% (5·8–20·5) 15 000 (7000–29 000) 124 000 134 000
Western Pacific 13·0% (6·5–23·7) 11·8% (5·2–22·5) 1·2% (0·4–2·6) 11·0% (5·5–20·1) 10 000 (2000–22 000) 74 000 87 000
Global average (all regions) 29·6% (22·9–37·1) 26·8% (19·7–34·5) 2·7% (1·0–6·0) 27·0% (20·8–33·9) 420 000 (317 000–546 000) 1 411 000 1 548 000

Data are % (95% UI), n (95% UI), or n. PAF=population attributable fraction. UI=uncertainty interval.

*

Includes incident HIV infections from all routes of transmission (not just sexual transmission).

Estimates are shown to the nearest thousand; they are based on 2016 HIV incidence data, 2012 HSV-2 infection estimates,1 RR estimates from a review of literature published up until 2017,6 and key population breakdown of HIV incidence for 2015.23

Denominators for calculation of PAFs of incident HIV infection via sexual transmission attributable to HSV-2 infection.

§

Denominators for calculation of PAFs of incident HIV infection via all routes of transmission attributable to HSV-2 infection.